Search

Background Glucagon-like peptide-1 receptor agonists provide effective hyperglycemia management in patients with type 2 diabetes. In a randomized head-to-head trial, liraglutide 1.8 mg q.d. led to greater reductions in HbA1c than exenatide 10 μg b.i.d. There are no direct comparisons of liraglutide 1.2 mg q.d. and exenatide b.i.d.; therefore, in the present study, an indirect comparison and meta-analysis were undertaken. Methods A systematic literature search was performed for randomized controlled trials of liraglutide 1.2 mg q.d. or exenatide b.i.d. with HbA1c as an outcome and ≥25 subjects. Key data were extracted and analyzed. A random-effects model was used to incorporate heterogeneity between studies. Results Three liraglutide 1.2 mg q.d. (n = 1060) and 10 exenatide b.i.d. (n = 2609) placebo-controlled studies were identified, allowing indirect comparison with placebo as the common arm. Baseline characteristics were mean age ~55 years, disease duration ~7 years, HbA1c ~8%, and body mass index ~32 kg/m2. Compared with exenatide b.i.d., liraglutide 1.2 mg was associated with significantly greater reductions from baseline in HbA1c (-0.29%; 95% confidence interval [CI] -0.53, -0.05) and fasting plasma glucose (-0.92 mmol/L; 95% CI -1.43, -0.41), with shorter duration of nausea (3 vs 14 days; P = 0.002) and fewer withdrawals (odds ratio 0.34; 95% CI 0.22, 0.52). The incidence of adverse events (including nausea) and withdrawals because of adverse events were similar between treatments. Conclusions Liraglutide 1.2 mg provided a significantly greater reduction in HbA1c than exenatide 10 μg b.i.d. The significantly shorter duration of nausea with liraglutide than exenatide may be appreciated by patients. [ABSTRACT FROM AUTHOR]

Gestational diabetes mellitus (GDM) is a global health concern, not only because its prevalence is high and on the increase, but also because of the potential implications for the health of mothers and their offspring. Unfortunately, there is considerable controversy in the literature surrounding the diagnosis and treatment of GDM, as well as the possible long-term consequences for the offspring. As a result, worldwide there is a lack of uniformly accepted diagnostic criteria and the advice regarding the treatment of GDM, including diet, insulin therapy, and the use of oral blood glucose-lowering agents, is highly variable. In this review we provide an overview of the important issues in the field of GDM, including diagnostic criteria, different treatment regimens available, and the long-term consequences of GDM in the offspring. [ABSTRACT FROM AUTHOR]

Background Syphilis, a sexually transmitted disease, is commonly referred to as the 'great imitator' because of its wide-ranging clinical presentations. Recently, we noticed that patients with neurosyphilis ( NS) seemed to be more susceptible to complications of diabetes mellitus ( DM). This is an interesting phenomenon, but it also puzzles clinicians because of scant knowledge about this situation. Methods A case-control study was conducted to explore the association between NS and DM. Clinical data and the prevalence of DM among NS patients, patients with syphilis but not NS (syphilis/non- NS), non-syphilis patients, and healthy controls were analyzed. In addition, we explored the time of occurrence of NS and DM. Results Fasting plasma glucose and HbA1c levels in NS patients were significantly higher than in syphilis/non- NS patients, non-syphilis patients, and healthy controls ( P < 0.05). In all, 45 of 149 NS patients (30.2%) were diagnosed with DM. The prevalence of DM in NS patients was significantly higher than in the other three groups ( P < 0.05). There was no relationship between the prevalence of DM and the type of NS (e.g. asymptomatic NS, syphilitic meningitis, meningovascular NS, general paresis, and tabes dosalis). In the study population, 57.8% of NS patients were diagnosed with DM at the same time, whereas 80.0% were diagnosed with DM within 5 years of their diagnosis of NS. Conclusions Based on the results of the present study, DM is not merely an occasional chance occurrence in NS patients. There is an association between NS and DM. [ABSTRACT FROM AUTHOR]